Solve pressing science, technological, and policy problems and make innovation happen. Apply your expertise, stretch your creative boundaries, and win cash awards ranging from $5,000 to $1 million — all the while helping advance human progress and making the world a better place...All Challenge postings and submissions are managed by InnoCentive.
Bispecific antibodies (BsAbs) can offer advantages over conventional monoclonal antibodies (mAbs) because they have the potential to modulate two specific pharmacologies simultaneously. This can lead to greater efficacy than is achieved by either single mAbs or even mAb combination therapy.
GSK has a strong interest in this emerging area of biopharmaceuticals, and has made and assessed many experimental BsAbs, as well as progressed a lead BsAb molecule to an experimental clinical study. For certain BsAb target pairings we have also seen early promise of differentiation from standard mAb combination approaches.
Whilst the best recognised medical application of BsAb use is in driving T-cell activation, GSK is also interested in ‘direct’ antibody actions, such as the inhibition or activation of conventional ligand/receptor target pairs.
GSK are therefore keen to work with the wider R&D community to understand if there are methods by which we can (i) predict the ability of any given target pair to act synergistically, and within this space (ii) predict target combinations that might be uniquely suitable to modulation by a BsAb, and therefore create medicines with the potential to be more efficacious than the equivalent mAb combination therapy.
This is an electronic Request-for-Partners (eRFP) Challenge; the Solver will only need to submit a written proposal to be evaluated by the Seeker with a goal of establishing a GSK funded collaborative partnership.
DEADLINE: Jan 06 2015 Project Rooms 76 Nov 20 2014